Genesys Venture
Genesys Venture Inc. is an accelerator firm based in Winnipeg, Canada, established in 1997 by bio-entrepreneur Dr. Albert D. Friesen. The firm specializes in the incubation and support of startup and early to mid-stage companies, focusing primarily on sectors such as life sciences, health technology, and biotechnology. Genesys Venture employs an enhanced incubation model that goes beyond traditional approaches, actively engaging with its client companies to provide a tailored mix of services. This hands-on involvement aims to successfully develop innovative technologies that address market opportunities, ultimately contributing to the growth of Manitoba-based businesses.
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. has a co-development agreement with GE Healthcare to expand provider access to TULSA-PRO. Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical Corp. operates as a medical technology company develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. has a co-development agreement with GE Healthcare to expand provider access to TULSA-PRO. Profound Medical Corp. is headquartered in Mississauga, Canada.
GVI Clinical Development Solutions Inc., a CRO, provides strategic consulting and clinical development support services to biotechnology, pharmaceutical, diagnostic, and medical device companies. Its strategic consulting services include medical needs assessment, clinical development planning, regulatory strategy, and business planning services. The company offers clinical trial planning services, such as protocol synopsis and full protocol development, investigator selection and contracting, clinical vendor selection, and resource needs planning and assessment services. It also provides clinical trial execution services, including clinical trial management and performance metrics, data collection and expedient trial close-out, sponsor and investigational staff training, on site monitoring, and pharmacovigilance services, as well as project management, clinical trial monitoring, drug safety, clinical data management, clinical and essential document control, and regulatory affair services. In addition, the company provides quality assurance and training services, such as clinical trial audits, process change, standard operating procedures development, and sponsor and clinical trial site staff training services. GVI Clinical Development Solutions Inc. is headquartered in Winnipeg, Canada.
Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms in Canada and internationally. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoos for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was founded in 2000 and is headquartered in Minneapolis, Minnesota.
Canam Bioresearch Inc. is a pharmaceutical contract research organization that specializes in pre-clinical discovery. The company offers synthetic organic chemistry and medicinal chemistry research services; analytical chemistry and bioanalysis services, such as HPLC-UV analysis, LC-MS analysis, plasma level analysis, blood level analysis, tissue distribution analysis, determination of chemical purity, certificates of analysis, and GC/MS EI analysis, as well as process monitoring, stability, and solubility determinations; and custom chemical synthesis and characterization services. It serves pharmaceutical companies and academic institutions. The company was founded in 2000 and is based in Winnipeg, Canada.